Q1 2026 Operating Profit Turns Positive, Dividend of 50 Won Per Share Maintained

Q1 2026 revenue of KRW 24.6 billion and operating profit of KRW 1.31 billion, swinging to profit from prior year (revenue +18%, net profit +33%).
Cash dividend of KRW 50 per share for FY2025 approved at AGM on March 27, 2026.
Transferred KRW 9.3 billion from capital reserve to retained earnings for financial flexibility.
Remaining convertible bond of KRW 23 billion (conversion price KRW 21,862, maturity 2028, with early redemption rights).
Ongoing appeal in lawsuit related to choline alfoscerate clinical reassessment (lost first trial, outcome uncertain).
R&D expenses of KRW 0.54 billion (2.19% of revenue); continued new product launches and pipeline expansion.
Net debt-to-equity ratio of 31.42%; holds KRW 29.45 billion in cash and cash equivalents, maintaining a stable financial structure.